PLx Pharma Inc. 4
4 · PLx Pharma Inc. · Filed Apr 21, 2017
Insider Transaction Report
Form 4
PLx Pharma Inc.PLXP
LUCI DAVID P
DirectorPresident, CEO, Secretary10% Owner
Transactions
- Award
Options
2017-01-17+275,000→ 275,000 totalExercise: $1.80Exp: 2022-01-17→ Common Stock (275,000 underlying) - Disposition to Issuer
Options
2017-04-19−298,826→ 0 totalExercise: $13.93From: 2014-03-18Exp: 2019-03-18→ Common Stock (298,826 underlying)
Footnotes (3)
- [F1]Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017.
- [F2]Option to purchase shares of common stock vested with respect to 137,500 shares on January 17, 2017, and with respect remaining 137,500 shares in connection with the merger (the "Merger") of a wholly-owned subsidiary of the Company with and into PLx Opco Inc. (formerly PLx Pharma Inc.).
- [F3]Option to purchase shares of common stock cancelled by mutual agreement of the reporting person and the Company in connection with the Merger.